Findings from the phase 2 PILOT study reveal lisocabtagene maraleucel to provide benefit as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation.
Results from the interim analysis of phase 3 KarMMa-3 study indicate improvement in progression-free survival with idecabtagene vicleucel compared with standard combination regimens, as well as better responses.
In an interview with Targeted OncologyTM, Debra Patt, MD, PhD, MBA, FASCO, discusses the impact of delayed cancer screenings in potential patients and how the COVID-19 pandemic has increased existing inequities in cancer care.
Results from a phase 2 study revealed nivolumab plus ipilimumab to demonstrate promising clinical activity and manageable safety signals in previously treated patients with classical Kaposi sarcoma who had disease progression.
Survival outcomes of avelumab in patients with PD-L1-positive non-small cell lung cancer showed numeric improvement compared with chemotherapy, but missed the significance threshold in the JAVELIN Lung 100 study.